miR-383-5p serves as a tumor suppressor in bladder cancer by suppressing PI3K/AKT signaling pathway

被引:6
作者
Liu, Yu [1 ,2 ]
Yu, Haitao [1 ]
Zeng, Bin [3 ]
Gou, Xin [1 ]
Ren, Ke [1 ]
Yuan, Fangchao [1 ]
机构
[1] Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China
[2] Chongqing Tradit Chinese Med Hosp, Dept Urol, Chongqing, Peoples R China
[3] Chongqing Med Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 2, Chongqing, Peoples R China
关键词
miR-383-5p; PI3KR1; AKT; bladder cancer; PROLIFERATION; MICRORNAS; MIGRATION; CELLS;
D O I
10.3233/CBM-220379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: MicroRNAs have been proven to be key molecules in human malignancy. However, to our knowledge, there is no study reporting miR-383-5p expression level and the role it plays in bladder cancer (BC). METHODS: We identified miR-383-5p to be one of the tumor-suppressing genes through using data from The Cancer Genome Atlas (TCGA) and GEO database. We evaluate the expression and activity of miR-383-5p in both BC tissue and cell lines. The impacts of miR-383-5p on proliferative, migratory ability and apoptotic rate in BC cell were evaluated by utilizing CCK-8 kits, flow cytometry, and Transwell assays. qRT-PCR, western blot, and luciferase reporter assays have been adopted to investigate the underlying mechanisms. In vivo tumorigenicity testing was conducted to determine the impact of miR-383-5p on BC cellular proliferative capacity. RESULTS: Reduced miR-383-5p expression has been determined in BC tissue than in normal bladder tissue. Furthermore, BC cell proliferative, migratory ability was inhibited while apoptosis enhanced in vitro and in vivo by miR-383-5p up-regulation. In vitro and in vivo, silencing miR-383-5p considerably improved the growth and invasive capacity of cell, while decreased the apoptotic rates of BC cells. CONCLUSION: miR-383-5p plays its role as a tumor-suppressing gene by suppressing the PI3K/AKT signaling, hence preventing the development of BC.
引用
收藏
页码:121 / 131
页数:11
相关论文
共 28 条
[21]   Down-Regulating the Expression of miRNA-21 Inhibits the Glucose Metabolism of A549/DDP Cells and Promotes Cell Death Through the PI3K/AKT/mTOR/HIF-1α Pathway [J].
Sun, Ye ;
Liu, Wenjun ;
Zhao, Qiuyu ;
Zhang, Ruiqi ;
Wang, Jianbo ;
Pan, Pengyu ;
Shang, Hai ;
Liu, Chunying ;
Wang, Chun .
FRONTIERS IN ONCOLOGY, 2021, 11
[22]   N6-Methyladenosine Modification of LncRNA DUXAP9 Promotes Renal Cancer Cells Proliferation and Motility by Activating the PI3K/AKT Signaling Pathway [J].
Tan, Lei ;
Tang, Yiming ;
Li, Hongbo ;
Li, Pengju ;
Ye, Yunlin ;
Cen, Junjie ;
Gui, Chengpeng ;
Luo, Junhang ;
Cao, Jiazheng ;
Wei, Jinhuan .
FRONTIERS IN ONCOLOGY, 2021, 11
[23]   Update on the guideline of guidelines: non-muscle-invasive bladder cancer [J].
Taylor, Jacob ;
Becher, Ezequiel ;
Steinberg, Gary D. .
BJU INTERNATIONAL, 2020, 125 (02) :197-205
[24]   Downregulated miR-383-5p contributes to the proliferation and migration of gastric cancer cells and is associated with poor prognosis [J].
Wei, Chao ;
Gao, Jian-Jun .
PEERJ, 2019, 7
[25]   Deoxyshikonin Inhibits Viability and Glycolysis by Suppressing the Akt/mTOR Pathway in Acute Myeloid Leukemia Cells [J].
Wu, Huijuan ;
Zhao, Hongmian ;
Chen, Li .
FRONTIERS IN ONCOLOGY, 2020, 10
[26]   MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer [J].
Zhang, Jingwei ;
Kong, Xia ;
Shi, Qizhu ;
Zhao, Bin .
CANCER BIOMARKERS, 2020, 27 (04) :423-432
[27]   MiR-383 inhibits proliferation, migration and angiogenesis of glioma-exposed endothelial cells in vitro via VEGF-mediated FAK and Src signaling pathways [J].
Zhao, Li-Ni ;
Wang, Ping ;
Liu, Yun-Hui ;
Cai, Heng ;
Ma, Jun ;
Liu, Li-Bo ;
Xi, Zhuo ;
Li, Zhi-Qing ;
Liu, Xiao-Bai ;
Xue, Yi-Xue .
CELLULAR SIGNALLING, 2017, 30 :142-153
[28]   MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A [J].
Zhao, Shasha ;
Gao, Xinyuan ;
Zang, Shuzhi ;
Li, Yunxia ;
Feng, Xianjun ;
Yuan, Xiaomei .
ONCOLOGY LETTERS, 2017, 14 (03) :3573-3579